期刊文献+

膜式血浆分离器血浆置换联合激素及免疫抑制剂治疗血栓性血小板减少性紫癜的疗效观察 被引量:11

Effect of plasma exchange with membrane plasma separator combined with glucocorticoids and immunosuppressive agents on thrombotic thrombocytopenic purpura
下载PDF
导出
摘要 目的观察膜式血浆分离器行血浆置换(PE)联合激素及免疫抑制剂治疗,对血栓性血小板减少性紫癜(TTP)的疗效。方法选取2013年1月-2014年2月在中南大学湘雅医院确诊为TTP并接受PE联合激素及免疫抑制剂治疗的住院患者9例,观察PE治疗前后患者临床症状及各项实验室指标的变化。结果 8例患者存活(5例完全缓解、3例好转),1例患者(原发性TTP合并多器官功能衰竭)PE 1次后死亡。PE治疗后患者神经系统症状有不同程度减轻,体温恢复正常;尿素氮(BUN)、血肌酐(Scr)无明显变化;血红蛋白(Hb)、血小板计数(Plt)较治疗前升高(P<0.01);乳酸脱氢酶(LDH)、间接胆红素(IBIL)较治疗前降低(P<0.01)。结论膜式血浆分离器行PE联合激素及免疫抑制剂治疗对TTP患者疗效明显。 [Objective] To investigate the effect of plasma exchange with membrane plasma separator combined with glucocorticoids and immunosuppressive agents on thrombotic thrombocytopenic purpura (TIP). [Methods] Nine patients with TIP, treated with plasma exchange combined with glucocorticoids and immuno- suppressive agents in Xiangya Hospital from January 2013 to February 2014, were studied. The main clinical and laboratory data before and after the treatment were analyzed. [Results] Eight patients survived (five at- tained a complete remission, three improved), and one patient (diagnosed as primary TFP with multiple organ failure) died after one plasma exchange. Neurological symptoms of the patients abated in various degrees and body temperature returned to normal after the treatment, hemoglobin level and plate count elevated (P〈 0.01); while lactic dehydrogenase (LDH) activity and indirect bilirubin (IBIL) concentration decreased (P〈 0.01). Blood urea nitrogen and serum creatinine concentration had no significant change after the treatment. [ Conclusion] Plasma exchange with membrane plasma separator combined with glucocorticoids and immunosuppressive a- gents is an effective treatment for TFP.
出处 《中国现代医学杂志》 CAS 北大核心 2015年第14期76-79,共4页 China Journal of Modern Medicine
基金 中南大学中央高校基本科研业务费专项资金(No:2013zzts313)
关键词 血栓性血小板减少性紫癜 血浆置换 激素 免疫抑制剂 疗效 thrombotic thromboeytopenic purpura plasma exchange glucocorticoid immunosuppressive a-gent treatment efficacy
  • 相关文献

参考文献14

  • 1BLOMBERY P, SCULLY M. Management of thmmhotic thrombo- cytopenic purpura: current pepectives[J]. Blood Med, 2014, 5: 15-23.
  • 2阮长耿,余自强.2012版血栓性血小板减少性紫癜诊断与治疗中国专家共识解读[J].临床血液学杂志,2013,26(2):145-146. 被引量:31
  • 3RUBIA JDL, LOPEZ A, ARRIAGA F, et al. Response to plasma exchange and steroids as combined therapy for patients with thrombotic thrombocytopenic purpura[J]. Acta Haematol, 1999, 102 (1): 12-16.
  • 4SCULLY M, HUNT BJ, BENJAMIN S, et al. Guidelines on the diagnosis and management of thrombotic thrombytopenic purpu- ra and other thrombotic microangiopathies[J]. Br J Haematol, 2012, 158(3): 323-335.
  • 5SPRINGER TA. Biology and physics of von willebrand faetnr concatamers[J]. J Thromb Haemost, 2011, 9(1): 130-143.
  • 6FEYS H, ANDERSON P], VANHOORELBEKE K, et al. Multi step binding of ADAMTS-13 to von willebrand factor[J]. J Thromb Haemnst, 2009, 7(12): 2088-2095.
  • 7SCHIVIZ A, WUERSCH K, PISKERNIK C, et al. A new mouse model mimicking thrombotic thrombytopenic purpura: correction of symptoms by reeombinant human ADAMTS13[J]. Blood, 2012, 119(25): 6128-6135.
  • 8PEREIRA A, MAZZARA R, MONTEAGUDO J, et al. Thrombot- ic thrombytopenie purpura/hemolytic uremic syndrome: a mul- tivariate analysis of facto prodicting the response to plasma ex- change[J]. Ann Hematol, 1995, 70(6): 319-323.
  • 9CRAWLEY JT, SCULLY MA. Thrombotic thrombocytopenic pur- pura: basic pathophysiology and therapeutic strategies[J]. Hema- tology Am Soc Hematol Educ Program, 2013, 1: 292-299.
  • 10ROCK G, SHUMAK KH, BUSKARD NA. et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombytopenic purpura. Canadian Apheresis Study Group[J]. N Engl J Med, 1991, 325(6): 393-397.

二级参考文献5

  • 1苏健,白霞,刘芳,高维强,余自强,王兆钺,阮长耿.血管性血友病因子裂解酶功能检测在血栓性血小板减少性紫癜诊断中的意义[J].中华检验医学杂志,2006,29(5):414-416. 被引量:1
  • 2SADLER J E. Von Willebrand factor,ADAMTS13,and thrombotic thrombocytopenic purpura[J]. Blood,2008,112:11-18.
  • 3SADLER J E, PONCZ M. Antibody-mediated throm-botic disorders : thrombotic thrombocytopenic purpuraand heparin-induced thrombocytopenia[M]//KAUS-HANSKY K,LICHTMAN M A’BEULTER E,et al.Williams Hematology. 8th ed. The McGraw-HillCompanies. Inc,2010:2163 - 2183.
  • 4KOKAME K,NOBE Y’KOKUBO Y,et al. FRETS-VWF73,a first fluorogenic substrate for ADAMTS13assay[J]. Br J Haematol, 2005,129 :93 -100.
  • 5BRESIN E,GASTOLDI S,DAINA E,et al. Ritux-imab as pre-emptive treatment in patients with throm-botic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies [J]. Thromb Haemost,2009,101:233-238.

共引文献30

同被引文献77

引证文献11

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部